Tilray Brands, Inc. - Common Stock (TLRY)
2.6100
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 12th, 9:02 AM EST
Detailed Quote
| Previous Close | 2.610 |
|---|---|
| Open | - |
| Bid | 2.560 |
| Ask | 2.600 |
| Day's Range | N/A - N/A |
| 52 Week Range | 2.485 - 15.70 |
| Volume | 40,529 |
| Market Cap | 1.91B |
| PE Ratio (TTM) | -2.691 |
| EPS (TTM) | -1.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,697,430 |
Chart
About Tilray Brands, Inc. - Common Stock (TLRY)
Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
News & Press Releases
10 Barrel Becomes the Portland Trail Blazers’ First Official Canned Cocktail Partner, Expanding Oregon Craft Beverages Across Moda Center and the Rip City Bar Network
By Tilray Brands, Inc. · Via GlobeNewswire · November 12, 2026
A Fresh Way to Experience Breckenridge Distillery Through Special Bottlings, Tastings and Behind-The-Scenes Access
By Tilray Brands, Inc. · Via GlobeNewswire · November 11, 2026
Earlier this year, the U.S. government announced it would reclassify certain medical cannabis products from Schedule I to Schedule III substances.
Via The Motley Fool · November 10, 2026
The company is consolidating Canadian operations in a move that will lead to annual cost savings of around $10 million.
Via The Motley Fool · November 9, 2026
Debt and cash flow reveal some significant differences.
Via The Motley Fool · November 8, 2026
Consolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings
By Tilray Brands, Inc. · Via GlobeNewswire · November 2, 2026
Tilray's ambition to move beyond marijuana has hit high gear, and it changes the company's story in a big way.
Via The Motley Fool · November 1, 2026
Cannabis is becoming a smaller part of Tilray's business.
Via The Motley Fool · November 1, 2026
Tilray commands a 4x revenue advantage, but Canopy's latest quarter hints at momentum—here's what the data reveals about their competitive positioning.
Via The Motley Fool · October 30, 2026
$100 from every bottle sold will benefit Denver men’s ice hockey scholarships
By Tilray Brands, Inc. · Via GlobeNewswire · October 29, 2026
Successfully Completed Consolidation of U.S. Brewing Footprint from 10 Facilities to Six
By Tilray Brands, Inc. · Via GlobeNewswire · October 29, 2026
The cannabis stock has generated nearly $1 billion in revenue over the past year, and its market cap is less than half of that.
Via The Motley Fool · October 27, 2026
Tilray's transformation is still ongoing, but it just reached a critical milestone.
Via The Motley Fool · October 25, 2026
Long Island’s Original Craft Brewery Invites Beer Fans to an Afternoon of Cask Ales, Live Music and Local Food Trucks at its 22nd Annual Festival
By Tilray Brands, Inc. · Via GlobeNewswire · October 22, 2026
By Tilray Brands, Inc. · Via GlobeNewswire · October 21, 2026
Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than the headline suggests.
Via The Motley Fool · October 20, 2026
The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable. Canopy is narrowing losses and targeting positive EBITDA by fiscal year-end.
Via The Motley Fool · October 15, 2026
Crack Open the Good Times: Fans 21+ Can Scan the SweetWater QR Code in or Enter Online for a Shot at a Night Out at Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West
By Tilray Brands, Inc. · Via GlobeNewswire · October 15, 2026
INFARMED approval authorizes Tilray Medical’s Cantanhede, Portugal facility to conduct microbiological and chemical/physical testing on-site, advancing pharmaceutical-grade quality control within its EU-GMP production platform
By Tilray Brands, Inc. · Via GlobeNewswire · October 13, 2026
The company's top line may have increased, but it doesn't take long for investors to spot problems in its recent earnings report.
Via The Motley Fool · October 12, 2026
Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.
Via The Motley Fool · October 10, 2026
Tilray's stock isn't the bargain it appears to be at first.
Via The Motley Fool · October 10, 2026
Tilray Brands' fiscal Q1 2027 results show beverage revenue up 82% and European medical cannabis growth offsetting weaker Canadian sales, reducing reliance on U.S. federal rescheduling.
Via MarketBeat · October 9, 2026
BrewDog profitability and record revenue signal diversified growth momentum.
Via The Motley Fool · October 8, 2026
Tilray Brands (NASDAQ:TLRY) reported record first-quarter revenue and gross profit, driven by its BrewDog acquisition, international cannabis growth and pharmaceutical distribution operations, while reaffirming fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million.
Net revenue rose 23%
Via MarketBeat · October 8, 2026
